DALLAS: It has been more than a decade since a new drug was approved for suffering memory loss from Alzheimer’s disease.
Alzheimer’s research has experienced prominent setbacks over the past decade, when promising drugs designed to reverse abnormalities in the brains of patients with the disease failed to show therapeutic benefit.
Research suggests that the failed drugs entered clinical trials before the underlying technologies were sufficiently mature.
“Research shows that very few clinical trials succeed when the underlying basic science is immature,” said …